Category - Developments

Developments

Zenabis arranges $30-million non-dilutive financing in supply pact with Tilray

Zenabis Global (TSX:ZENA) entered into an agreement with High Park Holdings, a wholly-owned unit of Tilray (NASDAQ:TLRY), for High Park to advance $30- million (Canadian) to Zenabis in return for a supply of dried...

July 2, 2019

Developments

vTv Therapeutics starts Phase 2 trial in patients with AD and T2D

vTv Therapeutics (NASDAQ:VTVT) initiated a Phase 2 trial of azeliragon in patients with Alzheimer’s disease (AD) and Type 2 diabetes (T2D).

June 29, 2019

Developments

Arcturus Therapeutics gets FDA orphan drug designation for ARCT-810

Arcturus Therapeutics (NASDAQ:ARCT) received FDA orphan drug designation for ARCT-810 for the treatment of ornithine transcarbamylase (OTC) deficiency.

June 29, 2019

Developments

Zogenix reaches agreement with FDA for FINTEPLA NDA resubmission

Following a Type A meeting with the FDA, Zogenix (NASDAQ:ZGNX) reported that it plans to resubmit its NDA for FINTEPLA for the treatment of seizures associated with Dravet syndrome.

June 27, 2019

Developments

Dova Pharma gets FDA sNDA approval for thrombocytopenia drug

Dova Pharmaceuticals (NASDAQ:DOVA) reported that the FDA approved DOPTELET’s supplemental NDA, expanding its use to include the treatment of adults with chronic immune thrombocytopenia (ITP) who have not responded to...

June 27, 2019

Developments

Aridis Pharma gets orphan drug designation for CF drug

Aridis Pharmaceuticals (NASDAQ:ARDS) received FDA orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF).

June 27, 2019

Developments

Novavax confirms accelerated approval pathway for NanoFlu

Novavax (NASDAQ:NVAX) reported that the FDA recently made the accelerated approval pathway available for NanoFlu, and that Novavax will be pursuing that pathway for licensure of the vaccine.

June 27, 2019

Developments

Zenabis joining Shoppers Drug Mart and TruTrace medical cannabis verification pilot

Zenabis Global (TSX:ZENA) will use TruTrace Technologies’ (CSE:TTT; OTC:BKKSF) StrainSecure platform to collect, register, manage, track and publish verified testing data of its cannabis plant DNA and strains, and...

June 27, 2019

Developments

ContraVir submits IND for CRV431 for NASH

ContraVir Pharmaceuticals (NASDAQ:CTRV) filed an IND with the FDA for CRV431 for the treatment of non-alcoholic steatohepatitis (NASH).

June 27, 2019

Developments

Titan Pharma, Molteni receive European regulatory okay for Probuphine

The European Commission approved Titan Pharmaceuticals’ (NASDAQ:TTNP) Sixmo, the brand name for its Probuphine implant in the European Union.

June 26, 2019

Category - Developments

Subscribe